BMP Signaling Mediated by BMPR1A in Osteoclasts Negatively Regulates Osteoblast Mineralization Through Suppression of Cx43

Ce Shi,[1,2] Honghao Zhang,[2] Ke'ale Louie,[2] Yuji Mishina,[2]* and Hongchen Sun[1]**

[1]*Department of Oral Pathology, School and Hospital of Stomatology, Jilin University, Changchun, Jilin Province 130021, China*

[2]*Department of Biologic and Materials Sciences, University of Michigan, School of Dentistry, Ann Arbor, Michigan 48109-1078*

ABSTRACT

Osteoblasts and osteoclasts are well orchestrated through different mechanisms of communication during bone remodeling. Previously, we found that osteoclast-specific disruption of one of the BMP receptors, *Bmpr1a*, results in increased osteoblastic bone formation in mice. We hypothesized that BMPR1A signaling in osteoclasts regulates production of either membrane bound proteins or secreted molecules that regulated osteoblast differentiation. In our current study, we co-cultured wild-type osteoblasts with either control osteoclasts or osteoclasts lacking BMPR1A signaling activity. We found that loss of *Bmpr1a* in osteoclasts promoted osteoblast mineralization in vitro. Further, we found that the expression of *Cx43/Gja1* in the mutant osteoclasts was increased, which encoded for one of the gap junction proteins connexin 43/gap junction alpha 1. Knockdown of *Gja1* in the mutant osteoclasts for *Bmpr1a* reduced osteoblastic mineralization when co-cultured. Our findings suggest that GJA1 may be one of the downstream targets of BMPR1A signaling in osteoclasts that mediates osteoclast–osteoblast communication during bone remodeling. J. Cell. Biochem. 118: 605–614, 2017. © 2016 Wiley Periodicals, Inc.

KEY WORDS: BMPR1A; OSTEOCLAST; OSTEOBLAST; CONNEXIN 43/GJA1; GAP JUNCTION

Bone remodeling is a dynamic process, which relies on the precise coordination of two principal cells within bone tissues: bone-formation activity of osteoblasts and bone-resorption activity of osteoclasts. It is well known that osteoblasts control osteoclast differentiation through cell–cell contact or paracrine, by expressing a number of factors, such as RANKL [Boyle et al., 2003], interleukin (IL) −1 [Lee et al., 2010] and −6 [Yoshitake et al., 2008], and tumor necrosis factor (TNF)-α [Atanga et al., 2011]. However, in the past few years, it is gradually recognized that osteoclasts do not just perform under the control of osteoblasts, they in turn influence osteoblasts as well. There are at least three modes of osteoclast–osteoblast communication. They can make direct contact, allowing membrane-bound ligands and receptors to interact and initiate intracellular signaling, i.e., family of ephrin ligands on osteoclasts and Eph receptors on osteoblasts [Edwards and Mundy, 2008], and family of semaphorins on osteoclasts and the corresponding receptors on osteoblasts [Kang and Kumanogoh, 2013]. Osteoclasts can form gap junctions allowing passage of small water-soluble molecules between the two cell types [Batra et al., 2012]. Second, osteoclasts secrete diffusible factors and act on osteoblasts via paracrine, such as sphingosine 1-phosphate (S1P) [Ryu et al., 2006], platelet-derived growth factor BB (PDGF BB) [Kubota et al., 2002; O'Sullivan et al., 2007], and hepatocyte growth factor (HGF) [Grano et al., 1996]. Third, during bone resorption, osteoclasts release growth factors and other molecules from bone matrix, such as transforming growth factor-β (TGF-β) [Ota et al., 2013] and insulin-like growth factor-I (IGF-I) [Hayden et al., 1995].

Recently, we disrupted *Bmpr1a*, encoding BMP receptor type IA (BMPR1A), in an osteoclast-specific manner using a knock-in Cre mouse line to the *cathepsin K* locus (*Ctsk* $^{Cre/+}$; *Bmpr1a* $^{flox/flox}$) [Okamoto et al., 2011]. We found that deletion of *Bmpr1a* in differentiated osteoclasts increased osteoblastic bone formation, suggesting that BMP signaling through BMPR1A in osteoclasts negatively regulates osteoblast differentiation. However, it is largely unknown how BMP signaling in osteoclasts regulates osteoclast–osteoblast communication. We hypothesized that BMP signaling mediated by BMPR1A in osteoclasts regulates production of either membrane bound proteins or secreted molecules that affects osteoblast differentiation. In addition, since *Ctsk*-Cre-expressing cells were recently found to display markers and functional properties consistent with mesenchymal progenitors [Yang et al., 2013], another possibility is that the phenotype we observed in *Bmpr1a* conditional knockout mice is due to disruption of *Bmpr1a* in *Ctsk*-Cre-expressing mesenchymal progenitors. To test the hypothesis that BMPR1A signaling in osteoclasts regulate osteoblast function through communication between two types of cells, and to explore the molecular mechanisms, it is necessarily and important to set up an in vitro co-culture system.

Gap junctions are clusters of intercellular channels formed from hexamers of connexins (Cx) that connect adjacent cells and allow for the diffusion of ions, small molecules, and second messengers between cells [Kumar and Gilula, 1996]. In bone, gap junctional intercellular communication (GJIC) mediated by connexins plays important roles in regulating signal transduction among different bone cells, thus influences development, differentiation, modeling, and remodeling of the bone. Connexin 43 (Cx43), also known as gap junction alpha-1 protein (GJA1) (encoded by *Gja1* gene), is a component of gap junctions. It is by far the most broadly and ubiquitously expressed member of the connexin family, being expressed in nearly all vital organs that include the brain, heart, bone, lungs, stomach, and intestine [Laird, 2006]. Among the members of the connexin family, Cx43/GJA1 is the most abundantly expressed in bone cells, including pre-osteoblasts, osteoblasts, osteocytes, and osteoclasts [Ilvesaro et al., 2000; Yellowley et al., 2000]. Physical contact of two adjacent cells facilitates the communication between the cells through Cx43/GJA1 [Lecanda et al., 2000; Meme et al., 2006]. It is known that Cx43/GJA1 positively regulates osteoblast differentiation and bone formation [Minkoff et al., 1999]. Besides, Cx43/GJA1 positively regulates osteoclastogenesis and bone resorption [Ransjo et al., 2003; Sternlieb et al., 2012]. Osteoclast–osteoblast interaction contributes to coupling of bone resorption and formation. However, GJIC between osteoclast and osteoblast is largely unknown.

In this study, to understand how BMP signaling in osteoclasts influences osteoblast differentiation, we co-cultured osteoclasts with osteoblasts in vitro and determined the extent of osteoblast mineralization which osteoclasts contributed to. We found that osteoclasts deficient for BMPR1A promoted osteoblast mineralization through up-regulation of a gap junction protein Cx43/GJA1 in osteoclasts. Our findings reveal a novel communication between osteoclasts and osteoblasts, which will further deepen understanding of bone biology.

MATERIALS AND METHODS

MICE

Generation of *Bmpr1a* null allele and conditional allele were previously reported [Mishina et al., 1995, 2002]. Mice heterozygous null for *Bmpr1a* carrying tamoxifen (TM)-inducible Cre fusion protein Cre-ER^{TM} under the ubiquitin promoter (no. 008085, The Jackson Laboratory) (*Bmpr1a* +/−: Ubi-CreER^{TM}) were bred with mice homozygous for the conditional allele for *Bmpr1a* (*Bmpr1a* fx/fx) [Mishina et al., 2002] (Fig. 1A) on a 12-h light/dark cycle. Mice genotyped *Bmpr1a* fx/+: Ubi-CreER^{TM} (+)/(−) were designated as control (cont), and *Bmpr1a* fx/−: Ubi-CreER^{TM} (+)/(−) within the same littermate as mutant (mut). All animal experiments were performed in accordance with the policy and federal law of judicious use of vertebrate animals as approved by the Institutional Animal Care and Use Committee (IACUC) at University of Michigan.

ISOLATION AND CULTURE OF OSTEOCLASTS

Control and mutant bone marrow cells were collected from the long bones (i.e., femora and humeri) of 1-month-old mice within littermates. After culturing overnight in α-MEM containing 10% fetal bovine serum (Hyclone) (full medium), non-adherent cells were harvested as bone marrow mononuclear cells (BMMCs). Proliferation of BMMCs was stimulated with 20 ng/ml Recombinant Murine Macrophage Colony Stimulating Factor (rmM-CSF) (PEPROTECH) for 4 days, followed by another 4 days of differentiation culture into osteoclasts using 20 ng/ml M-CSF and 50 ng/ml Recombinant Murine soluble Receptor Activator of NF-κB Ligand (rmRANKL) (PEPROTECH) [Yang et al., 2004]. Medium was changed every other day.

To determine efficacy of osteoclast formation, cells were differentiated using 20 ng/ml M-CSF and 50 ng/ml RANKL for 6 days, followed by tartrate-resistant acid phosphatase (TRAP) staining. The number of osteoclasts as well as the number of nuclei per osteoclast were counted. To determine bone resorption of osteoclasts, cells were seeded onto OsteoAssay Surface (Corning) and differentiated as stated above for 6 days. The resorption area was measured and was normalized by osteoclast number.

TM TREATMENT AND EVALUATION OF GENE RECOMBINATION

Ubi Cre-ER^{TM} activity was induced by administering 100 ng/ml of (Z)-4-hydroxytamoxifen (TM) (Sigma–Aldrich) in culture for 4 days [Kamiya et al., 2008]. After TM treatment, cells isolated from control (*Bmpr1a* fx/+: Ubi-CreER^{TM} (+)/(−)) and mutant (*Bmpr1a* fx/−: Ubi-CreER^{TM} (+)/(−)) mice were used as control and mutant cells, respectively. To detect Cre-dependent DNA recombination in *Bmpr1a*, genomic PCR was performed using primers fx1: 5′-GGTTTGGATCTTAACCTTAGG-3′ and fx4: 5′-TGGCTA-CAATTTGTCTCATGC-3 [Mishina et al., 2002]. This primer set generates a 180-bp amplicon after Cre-dependent recombination, while over 1.5-kb amplicon is generated if no recombination is occurred (Fig. 1B) [Mishina et al., 2002]. To quantify deletion of *Bmpr1a*, genomic real-time quantitative PCR was performed using TaqMan Gene Expression Assays (*Gapdh*: Cat. # 4352932E and *Bmpr1a*: custom designed to detect exon 4, SKU # 4331348) (Fig. 1B). Protein level of P-SMAD1/5/9, representing BMP-SMAD

Fig. 1. *Bmpr1a* was efficiently disrupted in undifferentiated and differentiated osteoclasts. (A) Breeding was set up between the mice indicated. Bone marrow cells were harvested and Cre activity was induced during culture. (B) Levels of recombination were evaluated by genomic PCR (fx1 and fx4) and quantitative genomic PCR for exon 4. (C) BMMCs were differentiated using 20 ng/ml M-CSF and 50 ng/ml RANKL and treated with TM for different days, followed by DNA extraction. Recombination levels were assessed by genomic PCR using primers fx1 and fx4. A 180-bp amplicon indicated Cre-dependent recombination, whereas an over 1.5-kb amplicon indicated no recombination. (D) BMMCs were treated with or without TM for 4 days in the presence of M-CSF only (undifferentiated) or differentiation medium (M-CSF and RANKL) (differentiated), followed by DNA extraction. Deletion efficiency of *Bmpr1a* locus was quantified by genomic real-time quantitative PCR. Levels of the presence of exon 4 were compared with the same stock of cells that were not treated with TM. (E) Control and mutant BMMCs were differentiated using M-CSF and RANKL for 4 days, and Cre activity was induced using tamoxifen at the same time. Then cells were stimulated with or without 100 ng/ml BMP-2 for 30 min, followed by cell lysis. P-SMAD1/5/9 level was detected by Western blot, and GAPDH was used as a loading control. (F) The scheme for osteoclast–osteoblast co-culture. BMMCs were expanded using M-CSF for 4 days and differentiated using M-CSF and RANKL for another 4 days. A total of 1×10^5 osteoclasts/well were added to osteoblast culture every 3 days in osteogenic differentiation medium. cont, control, genotyped as *Bmpr1a* fx/+, Ubi-CreER[TM] (+)/(−); mut, mutant, genotyped as *Bmpr1a* fx/−, Ubi-CreER[TM] (+)/(−); het, heterozygous; cKO, conditional knockout; bp, base pair; TM, (Z)-4-hydroxytamoxifen; ex, exon; BMMC, bone marrow mononuclear cell; OC, osteoclast; OB, osteoblast. $^*P < 0.05$; $^{**}P < 0.01$.

signaling pathway, in control and mutant osteoclasts after gene recombination was assessed by western blot. Differentiated osteoclasts were stimulated with or without 100 ng/ml recombinant human bone morphogenetic protein 2 (rhBMP-2) for 30 min before cell lysis.

OSTEOBLAST MONO-CULTURE AND CO-CULTURE

Primary calvarial pre-osteoblasts were isolated from 1- to 3-day-old wild-type mice as reported [Liu et al., 2013]. A total of 5×10^4 cells/well of osteoblasts were seeded in 24-well plate and the medium was changed to osteogenic differentiation medium (DM) (full medium containing 10 mM β-glycerophosphate and 50 μg/ml L-ascorbic acid) the next day. For osteoblast–osteoclast co-culture, 1×10^5 mature osteoclasts per well were added into osteoblast culture every

3 days and cultured in DM without M-CSF and RANKL (Fig. 1F). For each experiment, osteoclasts isolated from five control or mutant mice were pooled after confirmation of efficient Cre-dependent DNA recombination. Each experiment was repeated three times using different pooled samples.

ALIZARIN RED STAINING

After co-culture for 14 days, cells were stained with 40 mM alizarin red S (Sigma–Aldrich) for 10 min at room temperature. The number of alizarin red-stained nodules was counted. The percentage of nodule area was measured using Image J (RRID: SCR_003070). To minimize the effects of subjective bias when assessing the staining results, pictures were taken by one researcher (HZ), and measurements were performed by another researcher in a blinded manner

(CS). Then 10% w/v cetylpyridinium chloride (CPC) (Sigma–Aldrich) was used to dissolve bound alizarin red S and optical density was measured at 562 nm.

RNA ISOLATION AND QUANTITATIVE REAL–TIME RT–PCR

After BMMCs were differentiated for 4 days (total 8 days after isolation), osteoclasts were stimulated with or without 100 ng/ml recombinant human bone morphogenetic protein 2 (rhBMP-2, R&D Systems) for 6 h in full medium (10% serum). Total mRNA was isolated using TRIzol reagent (Life Technologies). For quantitative real-time RT-PCR analyses, equal amounts of RNA were reverse-transcribed using Superscript III first-strand synthesis System (Invitrogen) with oligo (dT) as a primer. The resulting cDNA templates were subjected to quantitative PCR using TaqMan probes (*Gapdh*: Mm99999915_g1; *Sema4d*: Mm00443147_m1; *Sema7a*: Mm00441361_m1; *Efnb2*: Mm00438670_m1; *Efna2*: Mm00433011_m1; *Acp5*: Mm00475698_m1; *Pdgfbb*: Mm00440677_m1; *Hgf*: Mm01135184_m1; *Cthrc1*: Mm01163611_m1; *Sphk1*: Mm00448841_g1; *Sphk2*: Mm00445021_m1; *Gja1*: Mm01179639_s1) by ABI PRISM 7500 (Applied Biosystems). Data were normalized to *Gapdh* expression using the $2^{-\Delta\Delta Ct}$ method.

Gja1 KNOCKDOWN ASSAY BY ADENOVIRUS TREATMENT

BMMCs were expanded using 20 ng/ml M-CSF for 4 days, and differentiated using 20 ng/ml M-CSF and 50 ng/ml RANKL for 2 days. The differentiated osteoclasts were transfected with vehicle control (Scrambled shRNA with GFP adenovirus, Ad-GFP-U6-shRNA, Vector Biolabs, Cat. no. 1122N) or mouse *Gja1* shRNA (Ad-GFP-U6-m-GJA1-shRNA, Vector Biolabs, no. shADV-280777) in serum free medium containing M-CSF, RANKL, and 200 PFU/cell (multiplicity of infection, MOI) of adenoviral vector stock for 3 h. Then the medium was replaced to full medium containing M-CSF and RANKL. Forty-eight hours after transfection, osteoclasts were trypsinized and added to osteoblast culture as mentioned above.

WESTERN BLOT ANALYSIS

Cells were lysed in RIPA buffer (20 mM Tris–HCl, 0.1% SDS, 1% Triton X-100, 1% sodium deoxycholate) containing protease inhibitor (Roche). The resulting lysates were run on 10% Mini-PROTEAN® TGX™ Gel (Bio-Rad) and transferred to Amersham Hybond-P membrane (GE Healthcare). The following antibodies were used (all are from Cell Signaling Technology): rabbit anti-connexin 43 (1:500, Cat. no. 3512, RRID: AB_2294590), rabbit anti-pSMAD1/5/9 (1:1000, Cat. no. 13820, RRID: AB_2493181), and rabbit anti-GAPDH (1:2000, Cat. no. 2118, RRID: AB_1031003). SuperSignal West Femto Chemiluminescent substrate was used to detect anti-connexin 43 and anti-pSMAD1/5/9, and Pico Chemiluminescent substrate (Thermo Scientific) was used to detect anti-GAPDH.

STATISTICAL ANALYSIS

All results were expressed as means ± standard deviation of triplicate measurements with all experiments independently repeated three times. Unpaired Student's *t*-tests were used to evaluate statistical differences. Values of $P < 0.05$ were considered significant.

RESULTS

Bmpr1a WAS EFFICIENTLY DISRUPTED IN OSTEOCLASTS

In differentiated osteoclasts, genomic PCR results showed the appearance of a 180-bp band as well as a significant reduction in the intensity of the non-recombination bands (>1500 bp) occurred as early as 2 days after TM treatment (Fig. 1C). Quantitative genomic real-time PCR results showed a significant reduction of exon 4 compared to the same cells cultured without TM (Fig 1D). In control cells (*Bmpr1a* fx/+: Ubi-CreER™ (+)/(−), one floxed allele with one wild-type allele, thus the maximum reduction of exon 4 is 50% after Cre-induced DNA recombination), we observed 38% and 27% reduction of the levels of exon 4 of *Bmpr1a* in undifferentiated and differentiated osteoclasts, while in mutant cells (*Bmpr1a* fx/−: Ubi-CreER™ (+)/(−), one floxed allele with one null allele), we observed 79% and 89% reduction in undifferentiated and differentiated osteoclasts. In control osteoclasts, BMP stimulation resulted in a strong signal of P-SMAD1/5/9, whereas in mutant osteoclasts, BMP stimulation did not increase P-SMAD1/5/9 level as observed in control osteoclasts (Fig. 1E, 70% reduction in mutant osteoclasts compared with control). Taken together, these results suggested efficient deletion of *Bmpr1a* in both undifferentiated and differentiated osteoclasts by 4 days of TM treatment as evidenced by the significant reduction of BMP-SMAD signaling activity.

BMPR1A NEGATIVELY REGULATED OSTEOCLAST FORMATION

First, we investigated the impact of the loss of BMPR1A signaling during osteoclastogenesis and resorption activity using in vitro system. After 6 days of culture in differentiation media, the *Bmpr1a* deficient cells showed higher number of osteoclasts compared with control (2.7-folds, Supplemental Fig. S1A). However, mutant osteoclasts were smaller in size with fewer nuclei (Supplemental Fig. S1B). In terms of bone resorption function per osteoclast, there was no significant difference between control and mutant osteoclasts (Supplemental Fig. S1C). These results suggested that disruption of *Bmpr1a* in osteoclasts increased osteoclast formation, but attenuated further differentiation to fuse together. BMPR1A deletion did not influence osteoclast resorption activity.

LOSS OF *Bmpr1a* IN OSTEOCLASTS PROMOTED OSTEOBLAST MINERALIZATION

Alizarin red staining showed that presence of osteoclasts promoted mineralization of osteoblasts (Figs. 1F and 2), i.e., co-culture showed higher number of mineralized nodules (1.6- and 2.9-folds in osteoblasts co-cultured with control and mutant osteoclasts, respectively, compared with osteoblast mono-culture), and larger area of mineralized nodules (3.1 and 8.3-folds in osteoblasts co-cultured with control and mutant osteoclasts, respectively, compared with osteoblast mono-culture), as well as more calcium deposit (16% and 32% increase in osteoblasts co-cultured with control and mutant osteoclasts, respectively, compared with osteoblast mono-culture), as quantified in Figure 2B. More

Fig. 2. Mutant osteoclasts deficient for *Bmpr1a* promoted osteoblast mineralization. (A) After co-culture for 14 days, cells were fix and stained for alizarin red. Comparison was done in triplicate. (B) The number of mineralized nodules was counted. The percentage of nodule area was measured and calculated. The staining was dissolved and the optical density was measured. Bar = 2 mm. cont, control; mut, mutant; OC, osteoclast; OB, osteoblast. $^{*}P < 0.05$; $^{**}P < 0.01$.

importantly, osteoclasts with disrupted *Bmpr1a* further promoted osteoblast mineralization (77% increase in nodule number, 2.6-fold in nodule area, and 14% increase in calcium deposit, in osteoblasts co-cultured with mutant osteoclasts compared with osteoblasts co-cultured with control osteoclasts) (Fig. 2). These results indicate that co-culture of osteoblasts with osteoclasts positively influences osteoblast mineralization, and suggest that BMP signaling through BMPR1A in osteoclasts indirectly, but negatively regulates osteoblast mineralization.

EXPRESSION OF GENES MEDIATING OSTEOCLAST–OSTEOBLAST COMMUNICATION WAS CHANGED

Since mutant osteoclasts promoted osteoblast mineralization in the co-culture system, we hypothesized that there were changes in mutant osteoclasts in secreted molecules or membrane bound proteins, which were involved in osteoclast–osteoblast communication. Based on published information, we selected 11 genes known to function in osteoclast–osteoblast communication and examined their expression [Grano et al., 1996; Kubota et al., 2002; Ryu et al., 2006; O'Sullivan et al., 2007; Edwards and Mundy, 2008; Batra et al., 2012; Kang and Kumanogoh, 2013; Takeshita et al., 2013]. We found that the expression of *Cr43/Gja1* was increased in mutant osteoclasts (approx. fourfolds) compared with control osteoclasts in the absence or presence of BMP2 (Fig. 3A). The expression of *Efna2* was decreased (∼30%) in mutant osteoclasts compared with control osteoclasts, in addition, 6 h of BMP2 treatment further lowered the expression of *Efna2* in both control and mutant osteoclasts (23% and 39% decrease in control and mutant osteoclasts, respectively, compared with no BMP2 treatment) (Fig. 3B). No overt changes were observed in other candidate genes (Fig. 3). EphrinA2 has been shown to mediate crosstalk between osteoclasts and osteoblasts [Irie et al., 2009], however, communication through Cx43/GJA1 between those two types of cells is largely unknown. Thus, we decided to further focus on *Cr43/Gja1* in this study.

KNOCKDOWN OF *Cx43/Gja1* IN OSTEOCLASTS DECREASED OSTEOBLAST MINERALIZATION

To explore a possibility that 6 h treatment was not enough or too long to observe the impact of BMP-2, we next examined the expression of *Cr43/Gja1* stimulated with BMP2 for different time periods. The expression of *Cr43/Gja1* decreased in both control and mutant osteoclasts after 6 h of stimulation, i.e., at 12 and 24 h (Fig. 4A), but the expression of *Cr43/Gja1* was significantly higher in the mutant osteoclasts at all time points examine. These results indicate that expression of *Cr43/Gja1* in osteoclasts was negatively regulated by BMP signaling, at least in part, through type 1A receptor.

To understand the role of Cx43/GJA1 in terms of osteoclast–osteoblast communication by knocking down *Cr43/Gja1* in mutant osteoclasts using adenovirus expressing shRNA. Strong GFP signal was detected 48 h after transduction that was also encoded by the adenovirus vector used for shRNA expression (Fig. 4B). The transduction efficiency based on the percentage of GFP positive cells was approximately 80%. Quantitative RT-PCR results showed that the expression of *Cr43/Gja1* did not change 24 h after transduction. At 48, 72, and 96 h after transduction, the expression of *Cr43/Gja1* decreased by ∼50%, compared with no transduction and scrambled shRNA (Fig. 4C). Cx43/GJA1 protein level revealed a 33% decrease at 48 h after transduction, an approximate 70% decrease at 72 and 96 h after transduction (Fig. 4D). These results suggested that *Cr43/Gja1* was efficiently knocked down, and protein level was significantly reduced in the condition we employed. According to the co-culture scheme (Fig. 1F), we treated osteoclasts with the adenoviruses 48 h before adding to the co-culture (Fig. 4F).

Consistent with Figure 2, alizarin red staining in Figure 5 confirmed that co-cultured osteoblasts with osteoclasts enhanced osteoblast mineralization, compared with osteoblast mono-culture (OB only); mutant osteoclasts further promoted osteoblast mineralization (OB + mut OC), compared with control osteoclast (OB + cont

Fig. 3. Osteoclastic expression profiles of candidate genes mediating osteoclast–osteoblast communication were changed. BMMCs were differentiated for 4 days, then cells were stimulated with or without BMP-2 for 6 h followed by RNA extraction. Quantitative RT–PCR was performed. Gene expression levels in control osteoclasts without BMP treatment were calculated as 1. cont, control; mut, mutant; OC, osteoclast. $^*P < 0.05$; $^{**}P < 0.01$.

OC) (Fig. 5). There was no difference between osteoblasts co-cultured with mutant osteoclasts (OB + mut OC) and mutant osteoclasts transduced scrambled shRNA (OB + mut OC sh-Scrb). However, after knocking down of Cr43/Gja1 in mutant osteoclasts, the mineralization was significantly decreased (OB + mut OC sh-Gja1) compared with osteoclasts transduced scrambled shRNA (OB + mut OC sh-Scrb), but still higher than osteoblast mono-culture (OB only) (Fig. 5A and B). These results suggested that BMP signaling mediated by BMPR1A in osteoclasts, at least in part, negatively regulated osteoblast mineralization through suppression of Cx43/GJA1.

DISCUSSION

Our present results demonstrated that osteoclasts deficient for BMPR1A promoted osteoblast mineralization in vitro. The expression of Cr43/Gja1 was up-regulated in mutant osteoclasts compared with control osteoclasts. Knockdown of Cr43/Gja1 in osteoclasts using shRNA decreased mineralization of osteoblasts

when co-cultured in vitro. Our findings suggested that Cx43/GJA1 encoded by Gja1 gene is one of the downstream targets of BMPR1A signaling in osteoclasts which mediates osteoclast–osteoblast communication.

Gap junctions and Cx43/GJA1 play important roles in osteoclasts, including osteoclast formation, resorption and communication in the bone multicellular unit in bone remodeling [Ilvesaro et al., 2000; Ilvesaro and Tuukkanen, 2003; Ransjo et al., 2003]. Cx43/GJA1 positively regulates osteoclastogenesis in vivo [Sternlieb et al., 2012]. Blocking of Cx43/GJA1 affects the fusion of larger osteoclasts with four or more nuclei [Hobolt-Pedersen et al., 2014]. The connexin mimetic peptide GAP 27, that inhibits GJIC, decreases the numbers of TRAP positive osteoclasts and increases the number of apoptotic osteoclasts [Ilvesaro et al., 2001]. Gap junction inhibitors AGA or oleamide leads to a significant inhibition of resorption pits formation on bone slice [Ransjo et al., 2003]. These experimental evidences suggest the crucial role of GJIC in conveying stimulating signaling on osteoclast formation, survival and resorption. We previously reported that BMPR1A in osteoclasts negatively regulates

Fig. 4. *Cx43/Gja1* was efficiently knocked down in osteoclasts by adenovirus treatment. (A) BMMCs were differentiated using M–CSF and RANKL for 4 days, then cells were stimulated with BMP–2 for different periods followed by RNA extraction. The expression of *Cx43/Gja1* was evaluated by quantitative RT–PCR. (B) Representative images of osteoclasts 48 h after transfection, showing GFP signals (lower panel) and the corresponding bright field (upper panel). (C) The expression of *Cx43/Gja1* after transfection. (D) Protein level of Cx43/GJA1 after transfection. (E) The scheme for co–culture when osteoclasts were treated with adenovirus. BMMCs were expanded using M–CSF for 4 days and differentiated using M–CSF and RANKL for another 4 days. Two days after differentiation, osteoclasts were transfected with adenovirus. A total of 1×10^5 osteoclasts/well were added to osteoblast culture every 3 days in osteogenic differentiation medium. cont, control; mut, mutant; OC, osteoclast; BF, bright field; GFP, green fluorescent protein; Ad, adenovirus; Scrb, scrambled. $^*P < 0.05$; $^{**}P < 0.01$.

osteoclastogenesis and bone resorption in vivo [Okamoto et al., 2011]. In vitro results using spleen cells indicates BMPR1A negatively regulates osteoclast formation and expression of osteoclast marker genes [Okamoto et al., 2011]. Together with the data shown in our current study, these results could be explained by increased *Cr43/Gja1* expression in the *Bmpr1a* mutant osteoclasts. In our current study, we found consistent results using bone marrow mononucleated cells, i.e., disruption of *Bmpr1a* increased osteoclastogenesis in vitro, reduced formation of multinucleated cells, and normal levels of resorption. Further investigation should shed a light on a molecular mechanism of how BMPR1A regulates osteoclastogenesis through Cx43/GJA1.

There are evidences showing that GJIC occurs between osteoblast–osteoblast, osteocyte–osteocyte, osteocyte–osteoblast, and osteoblast/osteocyte–osteoclast. Transmission of soluble molecules

via connexin gap junctions between osteoblasts allows propagation of specific signals and response to anabolic agents such as PTH [Lecanda et al., 1998; Stains and Civitelli, 2005; Chung et al., 2006]. Gap junctions at the tips of osteocyte cell processes respond to changes in the mechanical environment through stimuli such as mechanical loading, and transmit these signals through the osteocyte network to osteoblasts via gap junctions [Yellowley et al., 2000; Grimston et al., 2006; Bonewald, 2011]. In addition, GJIC plays an important role in osteoblast–osteocyte communication. Osteoblast/osteocyte specific *Cr43/Gja1* deficient mice have increased bone resorption and TRAP positive osteoclasts [Watkins et al., 2011; Zhang et al., 2011]. In vitro studies using *Cr43/Gja1* deficient MLO-Y4 cells, a cell line mimicking osteocyte characters, reveal an increase in the RANKL/OPG ratio, indicating that loss of *Cr43/Gja1* in osteocytes promotes osteoclastogenesis

Fig. 5. Mutant osteoclasts promoted osteoblast mineralization in the co–culture, and knockdown of *Cx43/Gja1* in mutant osteoclasts decreased osteoblast mineralization. (A) Cells were stained with alizarin red. Comparison was done in triplicate. (B) The number of mineralized nodules was counted. The percentage of nodule area was measured and calculated. The staining was dissolved and the optical density was measured. cont, control; mut, mutant; OC, osteoclast; OB, osteoblast; Ad, adenovirus; Scrb, scrambled. *$P < 0.05$; **$P < 0.01$.

[Zhang et al., 2011; Bivi et al., 2012]. Bone marrow stromal cells (BMSCs) are shown to communicate with each other and the bone lining cells via gap junctions [Doty, 1981; Dorshkind et al., 1993].

However, the knowledge of the functions of GJIC between osteoclasts and other cell types is still naive. In our current study, we demonstrated for the first time that disruption of *Bmpr1a* in osteoclasts promoted osteoblast mineralization through up-regulation of *Cr43/Gja1* in osteoclasts. It is possible to speculate that increased Cx43/GJA1 results in increased trafficking of small molecules from osteoclasts to osteoblasts through GJIC. Another possibility is that the up-regulation of *Cr43/Gja1* alters osteoclast functions that secondarily influence osteoblast functions. Besides its participation in gap junctions and hemichannels, Cx43/GJA1 might affect cellular function by interacting with structural molecules (such as caveolin-1 and 3 [Giepmans, 2004; Liu et al., 2010], tight junction protein ZO-1 [Giepmans, 2004], N-cadherin [Dbouk et al., 2009], alpha-catenin [Dbouk et al., 2009], tubulin [Giepmans, 2004]), kinase/phosphatase (such as Src, PKA, PKC [Giepmans, 2004]), growth suppression molecule CCN3/NOV [Giepmans, 2004], cell motility molecule ephrin [Davy et al., 2006], and other intracellular molecules (such as Cox-2, Hsp90, and beta-catenin [Dbouk et al., 2009]). The majority of these interactions are localized in areas of the cytoplasmic C-terminal tail of Cx43/GJA1, which does not

participate in channel formation [Giepmans, 2004; Dbouk et al., 2009]. Thus increased expression of *Cr43/Gja1* may also increase interactions with intracellular molecules in our mutant osteoclasts, which secondarily promotes osteoblast mineralization. The system we employed here does not exclude a possibility that osteoclasts regulate osteoblast differentiation through secretion factors. It is an interesting future effort to understand the mechanisms of how Cx43/GJA1 involves in communication between osteoclasts and osteo-blasts, especially necessity of direct cell–cell contact.

It is reported that BMP-2 induces expression of *Cr43/Gja1* in cardiomyocyte-like cells [Degeorge et al., 2008; Hou et al., 2013], in an in vitro mesenchymal cell condensation and chondrogenic differentiation model [Zhang et al., 2002], and in an embryonal mouse P19 cell line [Bani-Yaghoub et al., 2000]. While, in immortalized human granulosa cells, theca cell-derived BMP4 and BMP7 or oocyte-derived BMP15 down-regulates *Cr43/Gja1* expression and decreases GJIC activity [Chang et al., 2013, 2014]. It is also reported that BMP2, BMP4, and GDF5 can modulate *Cr43/Gja1* promoter activity in the osteosarcoma cell line ROS17/2.8, including positive and negative regulatory elements within *Cr43/Gja1* locus. Comparison of *Cr43/Gja1* promoter sequences from the human versus mouse showed five regions with significant sequence conservation, two of which contained SMAD binding elements in

conjunction with a BMP response element [Chatterjee et al., 2003]. In our current study, we found that BMP signaling mediated by BMPR1A down-regulated *Cr43/Gja1* expression in osteoclasts. These evidences suggest that BMP signaling differentially regulates *Cr43/Gja1* expression in a cell-type dependent manner. However, more detailed mechanisms need to be further addressed, including whether *Cr43/Gja1* is a direct downstream target of BMP signaling in osteoclasts, whether aforementioned putative BMP responsive elements in the promoter of *Cr43/Gja1* are involving in transcriptional regulation of *Cr43/Gja1* in osteoclasts.

In conclusion, our study identified that disruption of *Bmpr1a* in osteoclasts promoted osteoblast mineralization when co-cultured. Up-regulation of gap junction *Cr43/Gja1* in mutant osteoclasts is responsible for the enhanced osteoblast function. Our findings reveal a novel communication pathway between osteoclasts and osteoblasts, which will help in understanding of bone biology.

ACKNOWLEDGMENTS

AUTHORS' CONTRIBUTIONS

Study design was performed by CS, YM, and HS. Study conduct was performed by CS, HZ, and KL. Data collection was performed by CS, HZ, and KL. Data analysis was performed by CS. Data interpretation was performed by CS, HZ, YM, and HS. Drafting of paper was conducted by CS. Revision of the paper's content was performed by CS, HZ, KL, YM, and HS. CS, HZ, KL, YM, and HS approved the final version of paper. CS takes responsibility for the integrity of the data analysis.

REFERENCES

Atanga E, Dolder S, Dauwalder T, Wetterwald A, Hofstetter W. 2011. TNFalpha inhibits the development of osteoclasts through osteoblast-derived GM-CSF. Bone 49:1090–1100.

Bani-Yaghoub M, Felker JM, Sans C, Naus CC. 2000. The effects of bone morphogenetic protein 2 and 4 (BMP2 and BMP4) on gap junctions during neurodevelopment. Exp Neurol 162:13–26.

Batra N, Kar R, Jiang JX. 2012. Gap junctions and hemichannels in signal transmission, function and development of bone. Biochim Biophys Acta 1818:1909–1918.

Bivi N, Condon KW, Allen MR, Farlow N, Passeri G, Brun LR, Rhee Y, Bellido T, Plotkin LI. 2012. Cell autonomous requirement of connexin 43 for osteocyte survival: Consequences for endocortical resorption and periosteal bone formation. J Bone Miner Res 27:374–389.

Bonewald LF. 2011. The amazing osteocyte. J Bone Miner Res 26:229–238.

Boyle WJ, Simonet WS, Lacey DL. 2003. Osteoclast differentiation and activation. Nature 423:337–342.

Chang H-M, Cheng J-C, Taylor E, Leung PC. 2014. Oocyte-derived BMP15 but not GDF9 down-regulates connexin43 expression and decreases gap junction intercellular communication activity in immortalized human granulosa cells. Mol Hum Reprod 20:373–383.

Chang HM, Cheng JC, Leung PC. 2013. Theca-derived BMP4 and BMP7 down-regulate connexin43 expression and decrease gap junction intercellular communication activity in immortalized human granulosa cells. J Clin Endocrinol Metab 98:E437–E445.

Chatterjee B, Meyer RA, Loredo GA, Coleman CM, Tuan R, Lo CW. 2003. BMP regulation of the mouse connexin43 promoter in osteoblastic cells and embryos. Cell Commun Adhes 10:37–50.

Chung DJ, Castro CH, Watkins M, Stains JP, Chung MY, Szejnfeld VL, Willecke K, Theis M, Civitelli R. 2006. Low peak bone mass and attenuated anabolic response to parathyroid hormone in mice with an osteoblast-specific deletion of connexin43. J Cell Sci 119:4187–4198.

Davy A, Bush JO, Soriano P. 2006. Inhibition of gap junction communication at ectopic Eph/ephrin boundaries underlies craniofrontonasal syndrome. PLoS Biol 4:e315.

Dbouk HA, Mroue RM, El-Sabban ME, Talhouk RS. 2009. Connexins: A myriad of functions extending beyond assembly of gap junction channels. Cell Commun Signal 7:4.

Degeorge BR, Jr., Rosenberg M, Eckstein V, Gao E, Herzog N, Katus HA, Koch WJ, Frey N, Most P. 2008. BMP-2 and FGF-2 synergistically facilitate adoption of a cardiac phenotype in somatic bone marrow c-kit+/Sca-1+ stem cells. Clin Transl Sci 1:116–125.

Dorshkind K, Green L, Godwin A, Fletcher WH. 1993. Connexin-43-type gap junctions mediate communication between bone marrow stromal cells. Blood 82:38–45.

Doty SB. 1981. Morphological evidence of gap junctions between bone cells. Calcif Tissue Int 33:509–512.

Edwards CM, Mundy GR. 2008. Eph receptors and ephrin signaling pathways: A role in bone homeostasis. Int J Med Sci 5:263–272.

Giepmans BN. 2004. Gap junctions and connexin-interacting proteins. Cardiovasc Res 62:233–245.

Grano M, Galimi F, Zambonin G, Colucci S, Cottone E, Zallone AZ, Comoglio PM. 1996. Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. Proc Natl Acad Sci USA 93:7644–7648.

Grimston SK, Screen J, Haskell JH, Chung DJ, Brodt MD, Silva MJ, Civitelli R. 2006. Role of connexin43 in osteoblast response to physical load. Ann NY Acad Sci 1068:214–224.

Hayden JM, Mohan S, Baylink DJ. 1995. The insulin-like growth factor system and the coupling of formation to resorption. Bone 17:93S–98S.

Hobolt-Pedersen AS, Delaisse JM, Soe K. 2014. Osteoclast fusion is based on heterogeneity between fusion partners. Calcif Tissue Int 95:73–82.

Hou J, Lu AL, Liu BW, Xing YJ, Da J, Hou ZL, Ai SY. 2013. Combination of BMP-2 and 5-AZA is advantageous in rat bone marrow-derived mesenchymal stem cells differentiation into cardiomyocytes. Cell Biol Int 37:1291–1299.

Ilvesaro J, Tavi P, Tuukkanen J. 2001. Connexin-mimetic peptide Gap 27 decreases osteoclastic activity. BMC Musculoskelet Disord 2:10.

Ilvesaro J, Tuukkanen J. 2003. Gap-junctional regulation of osteoclast function. Crit Rev Eukaryot Gene Expr 13:133–146.

Ilvesaro J, Vaananen K, Tuukkanen J. 2000. Bone-resorbing osteoclasts contain gap-junctional connexin-43. J Bone Miner Res 15:919–926.

Irie N, Takada Y, Watanabe Y, Matsuzaki Y, Naruse C, Asano M, Iwakura Y, Suda T, Matsuo K. 2009. Bidirectional signaling through ephrinA2-EphA2 enhances osteoclastogenesis and suppresses osteoblastogenesis. J Biol Chem 284:14637–14644.

Kamiya N, Ye L, Kobayashi T, Lucas DJ, Mochida Y, Yamauchi M, Kronenberg HM, Feng JQ, Mishina Y. 2008. Disruption of BMP signaling in osteoblasts

through type IA receptor (BMPRIA) increases bone mass. J Bone Miner Res 23:2007–2017.

Kang S, Kumanogoh A. 2013. Semaphorins in bone development, homeostasis, and disease. Semin Cell Dev Biol 24:163–171.

Kubota K, Sakikawa C, Katsumata M, Nakamura T, Wakabayashi K. 2002. Platelet-derived growth factor BB secreted from osteoclasts acts as an osteoblastogenesis inhibitory factor. J Bone Miner Res 17:257–265.

Kumar NM, Gilula NB. 1996. The gap junction communication channel. Cell 84:381–388.

Laird DW. 2006. Life cycle of connexins in health and disease. Biochem J 394:527–543.

Lecanda F, Towler DA, Ziambaras K, Cheng SL, Koval M, Steinberg TH, Civitelli R. 1998. Gap junctional communication modulates gene expression in osteoblastic cells. Mol Biol Cell 9:2249–2258.

Lecanda F, Warlow PM, Sheikh S, Furlan F, Steinberg TH, Civitelli R. 2000. Connexin43 deficiency causes delayed ossification, craniofacial abnormalities, and osteoblast dysfunction. J Cell Biol 151:931–944.

Lee YM, Fujikado N, Manaka H, Yasuda H, Iwakura Y. 2010. IL-1 plays an important role in the bone metabolism under physiological conditions. Int Immunol 22:805–816.

Liu F, Fang F, Yuan H, Yang D, Chen Y, Williams L, Goldstein SA, Krebsbach PH, Guan JL. 2013. Suppression of autophagy by FIP200 deletion leads to osteopenia in mice through the inhibition of osteoblast terminal differentiation. J Bone Miner Res 28:2414–2430.

Liu L, Li Y, Lin J, Liang Q, Sheng X, Wu J, Huang R, Liu S, Li Y. 2010. Connexin43 interacts with Caveolin-3 in the heart. Mol Biol Rep 37:1685–1691.

Meme W, Calvo CF, Froger N, Ezan P, Amigou E, Koulakoff A, Giaume C. 2006. Proinflammatory cytokines released from microglia inhibit gap junctions in astrocytes: Potentiation by beta-amyloid. FASEB J 20:494–496.

Minkoff R, Bales ES, Kerr CA, Struss WE. 1999. Antisense oligonucleotide blockade of connexin expression during embryonic bone formation: Evidence of functional compensation within a multigene family. Dev Genet 24:43–56.

Mishina Y, Hanks MC, Miura S, Tallquist MD, Behringer RR. 2002. Generation of Bmpr/Alk3 conditional knockout mice. Genesis 32:69–72.

Mishina Y, Suzuki A, Ueno N, Behringer RR. 1995. Bmpr encodes a type I bone morphogenetic protein receptor that is essential for gastrulation during mouse embryogenesis. Genes Dev 9:3027–3037.

O'Sullivan S, Naot D, Callon K, Porteous F, Horne A, Wattie D, Watson M, Cornish J, Browett P, Grey A. 2007. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res 22:1679–1689.

Okamoto M, Murai J, Imai Y, Ikegami D, Kamiya N, Kato S, Mishina Y, Yoshikawa H, Tsumaki N. 2011. Conditional deletion of Bmpr1a in differentiated osteoclasts increases osteoblastic bone formation, increasing volume of remodeling bone in mice. J Bone Miner Res 26:2511–2522.

Ota K, Quint P, Ruan M, Pederson L, Westendorf JJ, Khosla S, Oursler MJ. 2013. TGF-beta induces Wnt10b in osteoclasts from female mice to enhance coupling to osteoblasts. Endocrinology 154:3745–3752.

Ransjo M, Sahli J, Lie A. 2003. Expression of connexin 43 mRNA in microisolated murine osteoclasts and regulation of bone resorption in vitro by gap junction inhibitors. Biochem Biophys Res Commun 303:1179–1185.

Ryu J, Kim HJ, Chang EJ, Huang H, Banno Y, Kim HH. 2006. Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast-osteoblast coupling. EMBO J 25:5840–5851.

Stains JP, Civitelli R. 2005. Gap junctions regulate extracellular signal-regulated kinase signaling to affect gene transcription. Mol Biol Cell 16:64–72.

Sternlieb M, Paul E, Donahue HJ, Zhang Y. 2012. Ablation of connexin 43 in osteoclasts leads to decreased in vivo osteoclastogenesis. J Bone Mineral Res 27:S53.

Takeshita S, Fumoto T, Matsuoka K, Park KA, Aburatani H, Kato S, Ito M, Ikeda K. 2013. Osteoclast-secreted CTHRC1 in the coupling of bone resorption to formation. J Clin Invest 123:3914–3924.

Watkins M, Grimston SK, Norris JY, Guillotin B, Shaw A, Beniash E, Civitelli R. 2011. Osteoblast connexin43 modulates skeletal architecture by regulating both arms of bone remodeling. Mol Biol Cell 22:1240–1251.

Yang CR, Wang JH, Hsieh SL, Wang SM, Hsu TL, Lin WW. 2004. Decoy receptor 3 (DcR3) induces osteoclast formation from monocyte/macrophage lineage precursor cells. Cell Death Differ 11(Suppl1):S97–S107.

Yang W, Wang J, Moore DC, Liang H, Dooner M, Wu Q, Terek R, Chen Q, Ehrlich MG, Quesenberry PJ, Neel BG. 2013. Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signalling. Nature 499:491–495.

Yellowley CE, Li Z, Zhou Z, Jacobs CR, Donahue HJ. 2000. Functional gap junctions between osteocytic and osteoblastic cells. J Bone Miner Res 15:209–217.

Yoshitake F, Itoh S, Narita H, Ishihara K, Ebisu S. 2008. Interleukin-6 directly inhibits osteoclast differentiation by suppressing receptor activator of NF-kappaB signaling pathways. J Biol Chem 283:11535–11540.

Zhang W, Green C, Stott NS. 2002. Bone morphogenetic protein-2 modulation of chondrogenic differentiation in vitro involves gap junction-mediated intercellular communication. J Cell Physiol 193:233–243.

Zhang Y, Paul EM, Sathyendra V, Davison A, Sharkey N, Bronson S, Srinivasan S, Gross TS, Donahue HJ. 2011. Enhanced osteoclastic resorption and responsiveness to mechanical load in gap junction deficient bone. PLoS ONE 6:e23516.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of this article at the publisher's web-site.